Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer

Citation for published version: Burn, J, Gerdes, A-M, Macrae, F, Mecklin, J-P, Moeslein, G, Olschwang, S, Eccles, D, Evans, DG, Maher, ER, Bertario, L, Bisgaard, M-L, Dunlop, MG, Ho, JWC, Hodgson, SV, Lindblom, A, Lubinski, J, Morrison, PJ, Murday, V, Ramesar, R, Side, L, Scott, RJ, Thomas, HJW, Vasen, HF, Barker, G, Crawford, G, Elliott, F, Movahedi, M, Pylvanainen, K, Wijnen, JT, Fodde, R, Lynch, HT, Mathers, JC, Bishop, DT & CAPP2 Investigators 2011, 'Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial' The Lancet, vol 378, no. 9809, pp. 2081-7., 10.1016/S0140-6736(11)61049-0

[1]  D. Bishop,et al.  A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.

[2]  R. Kucherlapati,et al.  Aspirin and Low-Dose Nitric Oxide–Donating Aspirin Increase Life Span in a Lynch Syndrome Mouse Model , 2011, Cancer Prevention Research.

[3]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[4]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[5]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[6]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[7]  D. Bishop,et al.  Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2008, The New England journal of medicine.

[8]  D. Bishop,et al.  Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Vasen.  Can the Identification of High Risk Groups Increase the Effectiveness of Colon Cancer Screening Programmes? , 2008, Zeitschrift fur Gastroenterologie.

[10]  L. Kopelovich,et al.  Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. , 2007, Cancer research.

[11]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[12]  P. Møller,et al.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[13]  P. Rothwell,et al.  Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies , 2007 .

[14]  B. Leggett,et al.  Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. , 2002, European journal of cancer.

[15]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[16]  D F Roychowdhury,et al.  Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[17]  J. Jass,et al.  Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? , 1995, Seminars in surgical oncology.